Terazosin Hydrochloride Capsule
Product Images NDC 87564-006

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Terazosin Hydrochloride (NDC 87564-006). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Amerisyn, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Terazosin 1mg 1000ct (Terazosin 1mg 1000ct)

Label for Terazosin Capsules, USP 1 mg oral capsules. The label shows the NDC number 87564-006-01 and states the product contains Terazosin Hydrochloride equivalent to 1 mg terazosin. It is Rx only and contains 1000 capsules. Manufactured for Amerisyn, LLC, Greensboro, NC, and by Aavis Pharmaceuticals, Hoschton, GA. Barcode and storage instructions are also visible.*

FDA Label Image

Terazosin 1mg 100ct (Terazosin 1mg 100ct)

Label for Terazosin Capsules, USP 1 mg by Amerisyn, LLC, in a 100 capsule package. The label includes directions to dispense the Medication Guide separately, storage instructions, and manufacturer details for Amerisyn, LLC and Aavis Pharmaceuticals. The NDC is 87564-006-10, and the label features a barcode alongside handling and dosage information.*

FDA Label Image

Terazosin 10mg 1000ct (Terazosin Cap 10mg 1000ct)

Label for Terazosin Capsules, USP 10 mg, oral capsule. The label states it is Rx only, contains 1000 capsules, and is manufactured for Amerisyn, LLC, Greensboro, NC, by Aavis Pharmaceuticals, Hoschton, GA. The label includes storage instructions, medication guide dispensing note, and a barcode.*

FDA Label Image

Terazosin 10mg 100ct (Terazosin Cap 10mg 100ct)

Terazosin Capsules, USP 10 mg oral capsules by Amerisyn, LLC. The label indicates 100 capsules per container with usage instructions, storage conditions, and warnings. The label includes a barcode and manufacturing details for Amerisyn, LLC and Aavis Pharmaceuticals.*

FDA Label Image

Terazosin 2mg 1000ct (Terazosin Cap 2mg 1000ct)

Terazosin Capsules, USP 2 mg capsule label shows the product name and strength prominently. It includes dispensing instructions, storage conditions, and warnings. The label indicates the product is manufactured for Amerisyn, LLC, made by Aavis Pharmaceuticals, and contains 1000 capsules. There is a barcode and a logo for Amerisyn.*

FDA Label Image

Terazosin 2mg 100ct (Terazosin Cap 2mg 100ct)

Label for Terazosin Capsules, USP 2 mg by Amerisyn, LLC. The label states the product is prescription-only with a quantity of 100 capsules. It includes storage instructions, dosage guidance, and manufacturer information for Amerisyn, LLC and Aavis Pharmaceuticals. A barcode and NDC 87564-007-10 are also visible.*

FDA Label Image

Terazosin 5mg 1000ct (Terazosin Cap 5mg 1000ct)

Label for Terazosin Capsules, USP 5 mg, oral capsule prescription drug. The label states each capsule contains 5 mg Terazosin Hydrochloride, with a package size of 1000 capsules. Manufactured for Amerisyn, LLC and by Aavis Pharmaceuticals. Includes dispensing instructions and storage conditions, along with barcode and NDC 87564-008-01.*

FDA Label Image

Terazosin 5mg 100ct (Terazosin Cap 5mg 100ct)

Label for Terazosin Capsules USP 5 mg by Amerisyn, LLC. It includes a pharmacist instruction, pack size of 100 capsules, NDC 87564-008-10, and storage info. Manufactured for Amerisyn, LLC by Aavis Pharmaceuticals. The label features dosage instructions, a barcode, and safety warnings.*

FDA Label Image

Terazosinhydrochloridechemicalstructure (Chemicalstructure)

Chemical structure of Terazosin Hydrochloride, showing the molecular composition including methoxy groups, an amino group, a piperazine ring, and a lactam moiety with a hydrochloride component.*

FDA Label Image

Figure1 (Figure1)

Two line charts showing comparative clinical data for Terazosin and placebo. The left chart illustrates mean change in total symptom score from baseline over three months for Terazosin and placebo groups. The right chart shows mean increase in peak flow rate (mL/sec) from baseline over the same period for Terazosin and placebo groups, with sample sizes noted for each group.*

FDA Label Image

Figure2 (Figure2)

A line graph showing mean change from baseline on the vertical axis over a 30-month period on the horizontal axis. Data points marked by circles indicate changes decreasing to about -5 to -6 units, with several points marked by asterisks highlighting statistically significant changes at earlier months.*

FDA Label Image

Figure3 (Figure3)

A line graph showing mean change from baseline measured in mL/sec over a 30-month period. The x-axis represents time in months from 0 to 30, and the y-axis represents mean change from baseline ranging approximately from 0.0 to 4.5. Data points with error bars indicate increasing values until about month 21, then a plateau, with several points marked by asterisks indicating statistical significance.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.